Comprehensive review of olopatadine: The molecule and its clinical entities

Allergy and Asthma Proceedings

Volumn 31, Issue 2, 2010, Pages 112-119

  Kaliner, Michael A ^a   Oppenheimer, John ^a   Farrar, Judith R ^a  

^a Institute for Asthma and Allergy   (United States)

Author keywords

Allergic conjunctivitis; Allergic rhinitis; Antihistamine; Mast cell stabilizer; Nasal allergy; Nasal antihistamine; Ocular allergy; Olopatadine

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; AZELASTINE; EPINASTINE; LORATADINE; MOMETASONE FUROATE; OLOPATADINE; PATADAY; PATANASE; PLACEBO; STEROID; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BITTER TASTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; GOLD STANDARD; HISTAMINE RELEASE; HUMAN; IN VITRO STUDY; MAST CELL; NONHUMAN; NOSE CONGESTION; OCULAR PRURITUS; PHARMACODYNAMICS; PRURITUS; QUALITY OF LIFE; REVIEW; RHINOCONJUNCTIVITIS; SIDE EFFECT; SKIN PRURITUS; TREATMENT RESPONSE; URTICARIA; VASOMOTOR RHINITIS;

ALLERGY AND IMMUNOLOGY; ANTI-INFLAMMATORY AGENTS; CELL DEGRANULATION; CLINICAL TRIALS AS TOPIC; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DIBENZOXEPINS; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG APPROVAL; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MAST CELLS; SOCIETIES, SCIENTIFIC; UNITED STATES;

EID: 77950841759     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3317     Document Type: Review

References (47)

1. Alcon Laboratories, Inc., Patanol (olopatadine hydrochloride ophthalmic solution) 0.1% prescribing information. Fort Worth, TX. 2009.
2. Alcon Laboratories, Inc., Pataday (olopatadine hydrochloride ophthalmic solution) 0.2% prescribing information. Fort Worth, TX. 2009.
3. Alcon Laboratories, Inc., Patanase (olopatadine hydrochloride) 665 mcg nasal spray prescribing information. Fort Worth, TX. 2009.
4. Nonaka H, Ishii A, and Kase H. Effect of KW-4679, a novel antiallergic agent, on histamine H1 receptor. Jpn J Pharmacol 61(suppl 1):87, 1993 (Abs O-83).
5. Sharif NA, Xu SX, and Yanni JM. Olopatadine (AL-4943A): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol 12:401-407, 1996.
6. Miki I, Kusano A, Ohta S, et al. Histamine enhanced the TNF- α-induced expression of E-selectin and ICAM-1 on vascular endothelial cells. Cell Immunol 171:285-288, 1996. (Pubitemid 26268486)
7. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Opthalmol 117:643-647, 1999.
8. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 88:379-397, 2002. (Pubitemid 34516564)
9. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 79:541-545, 1997.
10. Sasaki Y, Ikeda Y, Ikemura T, et al. Effect of KW-4679, an novel antiallergic drug on histamine and leukotriene release from rat peritoneal exudates cells. Clin Pharmacol Ther 5:1837-1849, 1995.
11. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J Ocul Pharmacol Ther 12: 389-400, 1996. (Pubitemid 26405743)
12. Brockman HL, Mornsen MM, Knudtson JR, et al. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm 11:247-268, 2003.
13. Cook EB, Stahl JL, Barnery NP, and Graziano FM. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 84:504-508, 2000. (Pubitemid 30365412)
14. Cook EB, Stahl JL, Barney NP, and Graziano FM. Olopatadine inhibits anti-immunolglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 87:424-429, 2000.
15. Ratner PH, James AJ, Orr SC, et al. The pharmacokinetics and cardiovascular safety of olopatadine in pediatric seasonal allergic rhinitis patients after administration of olopatadine HCl nasal spray. Presented at the American College of Allergy, Asthma, and Immunology 2007, Dallas, TX.
16. Beauregard C, Stephens D, Leighann R, et al. Duration of action of topical antiallergy drugs in a guinea pig model of histamine-induced conjunctival vascular permeability. J Ocul Pharmacol Ther 23:315-320, 2007. (Pubitemid 350195055)
17. Roy AK. Ocular tissue distribution of olopatadine following a single topical ocular dose of a 0.2% olopatadine ophthalmic solution to male New Zealand white rabbits. Alcon Internal Report 023:33:0502, 2002.
18. Vogelson CT, Abelson MB, Pasquine T, et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc 25:69-75, 2004. (Pubitemid 38365571)
19. Conjunctivitis. In The Allergy Report Vol. III: Conditions That May Have an Allergic Component. Milwaukee, WI: American Academy of Allergy, Asthma and Immunology, 1-16, 2000.
20. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agnet with dual activity, using conjunctival allergen challence. Ann Allergy Asthma Immunol 81:211-218, 1998.
21. Abelson MB, and Turner D. A randomized, double-blind, parallel- group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Ther 25:931-947, 2003. (Pubitemid 36459699)
22. Deschenes J, Discepola M, and Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand 77:47-52, 1999.
23. Lanier BQ, Finegold I, D'Arlenzo P, et al. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 20:1227-1233, 2004. (Pubitemid 39120787)
24. Finegold I, Granet DB, D'Arienzo PA, and Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: A post hoc analysis of data from a conjunctival allergen challenge study. Clin Ther 28:1630-1680, 2006. (Pubitemid 44848366)
25. Abelson MB, and Lanier RQ. The added benefit of local patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Acta Ophthalmol Scand 77:53-56, 1999.
26. Lanier BQ, Gross RD, Marks BB, et al. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann Allergy Asthma Immun 86:641-648, 2001.
27. Abelson MB, Gomes PJ, Vogelson CT, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhino-conjunctivitis: A randomized, double-masked environmental study. Clin Ther 26:1237-1248, 2004.
28. Abelson MB, Gomes PJ, Pasquine T, et al. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc 28:427-433, 2007.
29. Abelson MB, Gomes PJ, Vogelson CT, et al. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Curr Med Res Opin 21:683-691, 2005.
30. Mah FS, Rosenwasser LJ, Townsend WD, et al. Efficacy and comfort of olopoatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin 23:1445-1452, 2007. (Pubitemid 46998452)
31. Scoper SV, Berdy GJ, Lichtenstein SJ, et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv Ther 24:1221-1232, 2007.
32. Edwards MR, Pasquine T, Gross RD, and Robertson SM. Low frequency of treatment-related ocular adverse events associated with olopatadine 0.2% (Pataday) in clinical trials. Allergy Asthma Proc 28:249, 2007.
33. Mah FS, O'Brien T, Kim T, and Torkildsen G. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr Med Res Opin 24:441-447, 2008. (Pubitemid 351294393)
34. Lichtenstein S, Pasquine TA, Edwards MR, et al. Safety and tolerability of olopatadine 0.2% in children and adolescents. J Ocul Pharmacol Ther 23:366-371, 2007. (Pubitemid 350195061)
35. Jones JD, Temino VM, Dworski R, et al. Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. Allergy Asthma Proc 29:636-639, 2008.
36. Pipkorn P, Costantini C, Reynolds C, et al. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. Ann Allergy Asthma Immunol 101:82-89, 2008. (Pubitemid 352000749)
37. Patel P, Roland PS, Marple B, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 137:918-924, 2007. (Pubitemid 350117069)
38. Patel D, Garardi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
39. Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol 95:474-479, 2005. (Pubitemid 41688510)
40. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 95: 600-606, 2005. (Pubitemid 43010489)
41. Fairchild CJ, Meltzer EO, Roland PS, et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of olopatadine 0.6% and olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc 28:716-723, 2007.
42. Hampel FC, Ratner PH, Amar NJ, et al. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. Allergy Asthma Proc 27:202-207, 2006.
43. Shah SR, Nayak A, Ratner P, et al. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: A phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther 31:99-107, 2009.
44. Meltzer EO, Garadi R, Laforce C, et al. Comparative study of sensory attributes of two antihistamine nasal sprays: Olopatadine 0.6% and azelastine 0.1%. Allergy Asthma Proc 29:659-668, 2008.
45. Berger WE. Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis. Expert Opin Drug Metab Toxicol 5:91-102, 2009.
46. Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 mcg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 30:259-262, 2009.
47. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122(suppl 2):S1-S84, 2008. (Pubitemid 352033573)